Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2

Jennifer H. Stuart, Rebecca P. Sumner*, Yongxu Lu, Joseph S. Snowden, Geoffrey L. Smith*

Department of Pathology, University of Cambridge, Cambridge, United Kingdom

* Current address: Infection and Immunity, University College London, London, United Kingdom
* gls37@cam.ac.uk

Abstract

The type I interferon (IFN) response is a crucial innate immune signalling pathway required for defense against viral infection. Accordingly, the great majority of mammalian viruses possess means to inhibit this important host immune response. Here we show that vaccinia virus (VACV) strain Western Reserve protein C6, is a dual function protein that inhibits the cellular response to type I IFNs in addition to its published function as an inhibitor of IRF-3 activation, thereby restricting type I IFN production from infected cells. Ectopic expression of C6 inhibits the induction of interferon stimulated genes (ISGs) in response to IFNα treatment at both the mRNA and protein level. C6 inhibits the IFNα-induced Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway at a late stage, downstream of STAT1 and STAT2 phosphorylation, nuclear translocation and binding of the interferon stimulated gene factor 3 (ISGF3) complex to the interferon stimulated response element (ISRE). Mechanistically, C6 associates with the transactivation domain of STAT2 and this might explain how C6 inhibits the type I IFN signalling very late in the pathway. During virus infection C6 reduces ISRE-dependent gene expression despite the presence of the viral protein phosphatase VH1 that dephosphorylates STAT1 and STAT2. The ability of a cytoplasmic replicating virus to dampen the immune response within the nucleus, and the ability of viral immunomodulators such as C6 to inhibit multiple stages of the innate immune response by distinct mechanisms, emphasizes the intricacies of host-pathogen interactions and viral immune evasion.

Author Summary

In response to a viral infection, infected host cells mount an early, innate immune response to limit viral replication and spread. Type I interferons (IFNs) are produced by a cell when a viral infection is detected and are a crucial aspect of this early immune response. IFNs are released from the infected cell and can act on the infected cell itself or neighbouring cells to initiate a signalling pathway that results in the production of hundreds of anti-viral proteins. In this work we investigated a vaccinia virus protein...
Introduction

The innate immune response is the first line of defense against invading pathogens. Interferons (IFNs) are one of the key players in this early response to infection and are particularly important to protect against viruses, as can be seen by the increased susceptibility of IFNα/β receptor (IFNAR) knock out mice to viral infections [1]. There are two main branches to the IFN response; their production and the signaling initiated in response to the binding of secreted IFNs to their receptors at the cell surface.

Type I IFNs, which include IFNβ, several IFNα variants and other tissue or species-specific members, are produced directly in response to virus detection by cellular pattern recognition receptors (PRRs). Upon recognition of pathogen associated molecular patterns (PAMPs) such as viral DNA or RNA, PRRs activate several signaling pathways many of which converge on the kinases TANK-binding kinase (TBK1) and IκB kinase-ε (IKKe). These kinases, in complex with adaptor proteins such as TANK, NAK-associated protein 1 (NAP1) or similar to NAP1 TBK1 adaptor (SINTBAD), phosphorylate the transcription factor IFN regulatory factor 3 (IRF-3). Once phosphorylated, IRF-3 dimerises and translocates into the nucleus and, in combination with other transcription factors, drives transcription from promoters containing cognate binding sites, including the IFNβ promoter [2].

Once produced and secreted from cells, type I IFNs can act in a paracrine or autocrine fashion by binding to the IFNAR, which is composed of the two subunits IFNAR1 and IFNAR2. The binding of type I IFN to the receptor complex leads to the cross activation of the two Janus protein kinases, Tyk2 and Jak1 that are bound to the cytoplasmic domains of the IFNAR1 and IFNAR2, respectively. Once activated these kinases phosphorylate the transcription factors signal transducer and activator of transcription 1 (STAT1) and STAT2. These phosphorylated proteins then heterodimerise and bind to IRF-9 to form the IFN stimulated gene factor 3 (ISGF3) transcriptional activator complex. This tripartite complex translocates into the nucleus where it binds to IFN stimulated response elements (ISREs) found in the promoter of IFN stimulated genes (ISGs) and induces their transcription. The type I IFN signaling pathway and its regulation is reviewed in [3].

The importance of the IFN response for protection against viral infections is illustrated by the array of mechanisms and proteins used by viruses to evade and inhibit these cellular pathways, reviewed in [4]. Vaccinia virus (VACV) is a well-studied member of the Poxviridae and was the vaccine used in the eradication of smallpox [5]. It is a large DNA virus, with approximately 200 genes, that replicates exclusively in the cytoplasm of infected cells [6]. Between one third and one half of these 200 genes have been shown to have immunomodulatory or immuno evasion functions [7,8].
Many of these immunomodulatory proteins are able to inhibit type I IFN production, either through inhibition of the NF-κB pathway, for example VACV proteins B14 [9] and A49 [10], or through inhibition of the IRF-3 signalling pathway, as with VACV proteins A46 [11] and K7 [12]. In contrast, very few inhibitors have been identified that act post-IFN production. To date two VACV proteins are known to inhibit IFN signalling after type I IFN has been secreted from cells. B18 is a secreted VACV protein that binds type I IFN in solution and on the surface of cells and prevents its interaction with the IFNAR [13–15] and VH1 is a virally-encoded phosphatase that is packaged within virions [16] and dephosphorylates both STAT1 and STAT2, therefore acting as an intracellular inhibitor of JAK/STAT signalling [17,18].

C6 is a predicted member of the VACV Bcl2-like protein family, a family of 10 proteins whose previously studied members have various innate immune inhibitory functions [19–25]. It is expressed early during infection and its deletion attenuates the virus in both intranasal and intradermal models of infection in the mouse [26]. Despite being attenuated, VACV strains engineered to lack C6 showed enhanced immunogenicity in vivo [27,28]. Previously, C6 was shown to bind to the TBK1/IKKe adaptor proteins, SINTBAD, NAP1 and TANK, and prevents the TBK1/IKKe-dependent activation of IRF-3 and therefore inhibits the induction of type I IFNs [26]. Given many VACV proteins have been shown to have multiple functions, for example N1 that inhibits both NF-κB signalling [29] and apoptosis [23,30], and the observation that the hitherto only known function of C6 occurs in the cytoplasm of infected cells despite C6 being present in the nucleus and cytoplasm, we investigated whether C6 may have additional immunomodulatory functions.

In this study, VACV protein C6 is shown to be a dual function protein that inhibits type I IFN signalling as well as type I IFN production. Data presented show that the inhibition of IFNα-induced JAK/STAT signalling occurs at a late stage in the pathway, downstream of STAT phosphorylation, heterodimerisation, and nuclear translocation and downstream of ISGF3 binding to the ISRE, thus indicating an inhibitory function of C6 at or after formation of the transcriptional complex. Furthermore, C6 is shown to associate with the transcriptional activating domain (TAD) of STAT2, providing a plausible mechanism by which this viral protein could disrupt transcriptional complex formation. Interestingly, C6 was able to inhibit the transcriptional induction of all but one of the IFNα-dependent genes tested. This indicates that the step(s) inhibited by C6 downstream of ISGF3-ISRE interaction is likely to be conserved for a large number of ISGs, rather than a gene-specific transcriptional requirement. To our knowledge, this additional function of C6 makes C6 the first nuclear inhibitor of the IFN response encoded by the cytoplasmic-replicating DNA virus, VACV. The ability of VACV, a virus whose replication cycle takes place entirely within the cytoplasm of infected cells, to extend its influence into the host cell nucleus to inhibit crucial innate immune signalling pathways, highlights the complexity of virus-host interactions.

Results

C6 inhibits type I IFN signalling

Previously, C6 was characterised as an inhibitor of IFNβ production through inhibition of the IRF-3/7 signalling pathway [26]. However, many viral proteins are known to have multiple functions. To determine whether C6 was able to also inhibit signalling downstream of type I IFNs, its effect on the expression of an ISRE-dependent luciferase reporter gene (ISRE-luciferase) was assessed. HeLa and HEK293T cells were co-transfected with expression plasmids for ISRE-luciferase and V5- or TAP- tagged C6 or control proteins (S1 Fig). Cells were then stimulated with IFNα for 8 h and the expression of luciferase was measured by luminescence. Treatment of HEK293T and HeLa cells with IFNα led to an induction of luciferase expression and
in both cell types this induction was significantly inhibited by the co-expression of either TAP-C6 (p<0.0001 and p<0.01 respectively) or C6-V5 (p<0.001 and p<0.001 respectively, Fig 1A and 1B). As expected the positive controls Nipah Virus V protein (NiV-V) and Parainfluenza virus 5 V protein (PiV5-V) that are known to inhibit IFN signalling [31,32] also inhibited IFNα-induced luciferase expression, whilst expression of GFP or VACV protein B14 had no inhibitory effect.

To confirm the ability of C6 to inhibit type I IFN signalling, the effect of C6 on the induced transcription of endogenous ISGs was assessed next. HeLa cells stably expressing GFP alone (EV) or GFP in combination with V5 tagged C6, PiV5-V or B14 were stimulated with IFNα for 8 h. RNA was extracted from these cells and used for qPCR analysis of ISG mRNA expression. IFNα treatment of cells resulted in induction of the well-characterised ISGs tested, including interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), IFIT3 and MxA. The presence of C6 significantly inhibited the induction of gene expression when compared to both the EV and B14 controls (Fig 1C). Once again PiV5-V expression also inhibited the induction of ISG expression as expected (Fig 1C).

Finally, these stably transduced cells were used to confirm the ability of C6 to inhibit IFNα-induced gene expression at the protein level using flow cytometry analysis of IFIT1 expression. Cells were stimulated with IFNα for 8 h and then fixed, permeabilised and stained with an anti-IFIT1 antibody. Stained cells were analysed by flow cytometry to assess for IFIT1 protein expression. Once again treatment of EV transduced cells with IFNα resulted in an induction of IFIT1 expression, which was significantly inhibited by expression of C6 or the positive control, PiV5-V (p<0.01, Fig 1D). In contrast, expression of B14 had no effect on IFIT1 expression. Together these data show that C6 inhibits IFNα-mediated gene expression at both the mRNA and protein level.

The ability of C6 to inhibit signalling downstream of IFNα treatment, is not a result of its ability to inhibit TBK1/IKKe function

The IRF-3 signalling pathway is initiated in response to detection of viral RNA, DNA or proteins by PRRs in the cell and leads to the activation of the kinases TBK1 and IKKe. These kinases then phosphorylate IRF-3 causing its translocation into the nucleus from where it drives transcriptional activation of a number of target genes including IFNβ. C6 inhibits IRF-3 signalling at the level of TBK1 and IKKe, preventing the nuclear translocation of IRF-3 [26]. Several studies have described potential crosstalk between the IRF-3 and JAK/STAT signalling pathways, which together constitute the type I IFN response. In addition, IRF-3 is known to cause the transcriptional activation of a subset of ISRE containing gene promoters directly [33] and an additional phosphorylation event on STAT1 by IKKe is required for the full induction of approximately 30% of IFNα-responsive ISGs [34].

To rule out that the inhibitory effect of C6 on type I IFN signalling was an indirect consequence of its ability to interfere with TBK1 and IKKe function, and that this inhibitory activity was instead a novel function for C6, the effect of a TBK1/IKe specific inhibitor, BX795, on the ISRE-dependent reporter gene assay was assessed. Cells transfected with the ISRE-luciferase reporter were treated for 3 h with BX795 before stimulation with IFNα for a further 6 h in the continued presence of BX795. BX795 treatment had no inhibitory effect on the IFNα-dependent induction of firefly luciferase in the cells tested, when compared to a carrier (dimethyl sulphoxide, DMSO)-treated control (S2 Fig). To confirm the effectiveness and specificity of BX795 in this assay, BX795 treatment was also used in conjunction with firefly luciferase under the control of promoters responsive to the IRF-3 and NF-κB signalling pathways. Cells transfected with these luciferase reporters were stimulated with polyI:C and IL-1β
Fig 1. VACV protein C6 inhibits IFNα induced ISG expression. HEK-293T (A) and HeLa (B) cells were co-transfected in triplicate with an ISRE-luciferase reporter, a plasmid expressing renilla luciferase constitutively and expression vectors for the proteins shown. Twenty four hours post transfection cells were stimulated with 25 U/ml IFNα for 8 h. Firefly luciferase activity was measured by luminescence and normalised to a renilla luciferase expression as a control for transfection efficiency. (C and D) HeLa cells stably expressing the proteins shown were stimulated with 500 U/ml IFNα for 8 h. (C) mRNA was harvested from cells and used for qPCR analysis of ISG induction. (D) Cells were fixed.
respectively. Whilst treatment with BX795 had no effect on IL-1β-induced activation of the NFκB reporter gene, the induction of the IRF-3-responsive promoter by poly I:C was significantly reduced (p < 0.001), indicating that the inhibitor was effective at the doses used (S2 Fig). These data indicate that inhibition of TBK1 and IKKe does not cause the inhibition of ISRE-dependent gene expression that is seen in the presence of C6, implying that this is instead a novel function of C6.

C6 does not inhibit the IFNα-induced phosphorylation or dimerisation of STAT1 and STAT2

To determine how C6 inhibits the cellular response to IFNα, the phosphorylation status of STAT1 and STAT2 in cells expressing C6 following IFNα treatment was examined. HeLa cells stably expressing C6 or control proteins were stimulated with IFNα for 45 mins. Cell lysates were used for immunoblot analysis of levels of phosphorylated STAT1 and STAT2, including quantification of proteins using Odyssey software (LICOR). Neither C6 nor the negative control protein B14 inhibited the IFNα-induced phosphorylation of STAT1 or STAT2, whereas PiV5-V protein inhibited the phosphorylation of both proteins as expected (Fig 2).

Following phosphorylation, STAT1 and STAT2 heterodimerise and bind to IRF9 to form the ISGF3 complex. This complex then translocates into the nucleus where it drives expression of genes with an ISRE in their promoter. To determine whether C6 prevents the dimerisation of STAT1 and STAT2, an immunoprecipitation of STAT1 from IFNα-stimulated cells was performed in cells transiently transfected with C6 or N1, a VACV Bcl-2-like protein that does not inhibit IFNα signalling. Immunoblot analysis showed that following IFNα stimulation an increased amount of STAT2 was found associated with STAT1. However, C6 did not alter the amount of STAT2 bound to STAT1 either before or after stimulation (Fig 3).

C6 inhibits IFNα signalling at a step downstream of ISGF3 complex nuclear translocation

Following its formation, the ISGF3 complex translocates into the nucleus. To assess whether this nuclear translocation was inhibited by C6 the localization of STAT1 and STAT2 before and after IFNα stimulation was assessed by confocal microscopy. HeLa cells stably expressing GFP alone (EV) or in combination with V5-tagged C6 or PiV5-V were stimulated with 500 U/ml IFNα for 1 h. Cells were then fixed, permeabilised and stained for endogenous STAT1 (Fig 4A) or STAT2 (Fig 5A). Following IFNα stimulation the percentage of cells showing a nuclear stain for STAT1 and STAT2 increased to approximately 50% (Fig 4B) and 70% (Fig 5B), respectively. These localization patterns were not altered by C6 or the negative control, EV. The localisation of STAT1 could not be assessed in PiV5-V expressing cells due to its degradation by this viral protein, however, PiV5-V expression inhibited the translocation of STAT2 completely (Fig 5A). Together these data indicate that C6 does not inhibit the pathway prior to ISGF3 complex formation and nuclear translocation.

To obtain additional evidence that the inhibitory effect of C6 on IFNα signalling is downstream of ISGF3 complex formation, a plasmid encoding IRF-9 fused to the C-terminal region (amino acids 747–851) of the transcriptional activation domain of STAT2 (referred to as IRF9-S2C) was utilised. Previously, this fusion protein, which overcomes the need for ISGF3

**p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001.
complex formation, has been shown to act as a constitutively active ISGF3-like transcriptional activator in the absence of IFN stimulation [35]. When a plasmid encoding IRF9-S2C was co-transfected into HEK293T cells along with the ISRE-luciferase reporter gene, a large increase in firefly luciferase expression was observed in cells expressing IRF9-S2C relative to those transfected with empty vector (EV) only (Fig 6, columns 1 and 2). Interestingly, when co-transfected into cells, C6 inhibited IRF9-S2C-driven ISRE reporter activity significantly ($p < 0.0001$), whereas, neither PiV5-V protein nor NiV-V protein showed any inhibitory activity (Fig 6). This is in keeping with the known ability of these two viral proteins to inhibit the IFN$\alpha$ signalling pathway upstream of ISGF3 complex formation [31,32]. These data confirm that C6 inhibits IFN$\alpha$ signalling at a late stage following ISGF3 complex formation.

C6 does not prevent the binding of IRF9-S2C to the ISRE

To establish whether C6 inhibited IFN$\alpha$ signalling by preventing the binding of the ISGF3 complex to the ISRE in promoters of ISGs, the ability of the IRF9-S2C fusion protein to bind the ISRE was assessed. HEK293T cells were transfected with plasmids expressing IRF9-S2C and V5-tagged C6 or control proteins and cell lysates were harvested 16 h later. A biotin-labelled ISRE probe optimised previously for ISGF3 binding (ISREcore) [36], or a control biotin-labelled ISRE sequence that was shown to lack ISGF3 binding (ISRErandom) [36] were incubated with cell lysates and streptavidin beads were used to immunoprecipitate the
biotinylated DNA probe and associated proteins. C6 or GFP expression did not inhibit the binding of either IRF9-S2C or endogenous STAT2 to the biotin-labelled ISRE (Fig 7). In contrast, NiV-V protein was able to inhibit endogenous STAT2 binding to the ISRE but not binding of the IRF9-S2C construct as expected (Fig 7). Neither IRF9-S2C nor endogenous STAT2 bound to the ISRErandom control sequence as expected. Ku70, a known DNA binding protein, was used here as a control for DNA input and gel loading and was found to bind to both the ISREcore and ISRErandom DNA probes.

C6 associates with the transactivation domain of STAT2

To investigate whether C6 interacts with any of the components of the ISGF3 complex, an immunoprecipitation assay using FLAG-tagged STAT1, STAT2 and IRF-9 was performed. Plasmids expressing these proteins were co-transfected into HEK293T cells along with a V5-tagged C6 expression vector. Immunoprecipitation with anti-FLAG beads co-precipitated C6 with STAT2 but not with STAT1 or IRF-9 (Fig 8A).

To determine if the interaction between C6 and STAT2 was affected by IFN stimulation, HeLa cells were transfected with plasmids expressing HA-tagged STAT2 and either TAP-tagged C6 or N1 then mock-stimulated or stimulated with IFNα prior to immunoprecipitation (Fig 8B). This showed that the interaction between C6 and STAT2 did not require prior stimulation with IFN.

To confirm the interaction between C6 and STAT2 and to ascertain whether it occurs at endogenous protein levels and during viral infection, HEK293T cells were infected with
Fig 4. C6 does not inhibit the IFNα-induced nuclear translocation of STAT1. (A) HeLa cells stably expressing the stated proteins were stimulated with IFNα (1000 U/ml) for 1 h. Cells were then fixed, permeabilised and stained for STAT1. Protein localisation was determined by confocal microscopy. Three slides of each condition were made and one hundred GFP-positive cells on each slide were examined. The percentage of cells with a nuclear STAT1 (B) protein stain is shown.

doi:10.1371/journal.ppat.1005955.g004
Fig 5. C6 does not inhibit the IFNα-induced nuclear translocation of STAT2. (A) HeLa cells stably expressing the stated proteins were stimulated with IFNα (1000 U/ml) for 1 h. Cells were then fixed, permeabilised and stained for STAT2. Protein localisation was determined by confocal microscopy. Three slides of each condition were made and one hundred GFP-positive cells on each slide were examined. The percentage of cells with a nuclear STAT2 (B) protein stain is shown.

doi:10.1371/journal.ppat.1005955.g005
VACVs expressing TAP-tagged C6 or N1 under the natural promoters for these genes. Cells were then lysed and immunoprecipitations were performed against the FLAG epitope in the TAP tag of these viral proteins. Once again C6 associated with STAT2 and not STAT1, whilst N1 did not associate with either protein (Fig 8C), confirming the specific interaction between STAT2 and C6 at endogenous protein levels during viral infection.

As C6 inhibits IFNα signalling initiated by IRF9-S2C expression, its ability to interact with this fusion protein, which contains only the C-terminal 104 aa of the STAT2 transactivation domain, was assessed. To this end, HEK293T cells were co-transfected with either IRF9-S2C or HA-IRF-9 and C6-TAP or N1-TAP. Immunoprecipitation with anti-FLAG beads showed...
association between IRF9-S2C and C6 but not between C6 and HA-IRF-9 (Fig 8D). This indicates that C6 associates with the final 104 aa of the STAT2 transactivation domain, a region known to be important for recruitment of downstream chromatin modifying enzymes and transcriptional machinery.

C6 contributes to inhibition of ISRE-dependent gene expression during VACV infection

Finally, the biological importance of C6 for inhibition of the JAK-STAT pathway leading to activation of the ISRE promoter was assessed during VACV infection. The activity of C6 in

**Fig 7.** C6 does not prevent the binding of IRF9-S2C or endogenous STAT2 to the ISRE. HEK293T cells were transfected with plasmids expressing IRF9-S2C (lanes 1–9) and either V5-tagged C6 (lanes 1, 4 and 7), NiV-V (lanes 2, 5 and 8) or GFP (lanes 3, 6 and 9). Sixteen hours post transfection cells were harvested and lysates were incubated with poly(I:C) for 30 min. Biotin-labelled ISRE probes (ISREcore lanes 4–6, and ISRErandom lanes 7–9) were then added for 1.5 h before addition of streptavidin agarose beads for a further 3.5 h. Beads were washed four times and proteins were eluted and subjected to SDS-PAGE and immunoblotting (A). Band intensities were quantified and normalised to Ku70 immunoprecipitation (B). Immunoblots were performed at least twice and a representative figure is shown. Positions of molecular mass markers are shown to the left of the immunoblots. **p<0.01.

doi:10.1371/journal.ppat.1005955.g007
blocking this pathway was likely to be masked to some degree during infection by the presence of the virus phosphatase VH1, which dephosphorylates STAT1 and STAT2 and is delivered into cells by the invading virion immediately after infection. Therefore, two methods were used to assess if C6 contributed to the inhibition of the JAK-STAT pathway during infection. One method was simply to transfect the ISRE-luciferase reporter plasmid into cells 16 h before the cells were infected with either wt VACV or the vΔC6 mutant and then measure ISRE-luciferase at different times p.i. Preliminary experiments established that infection of cells at 5 PFU/cell for 5 h was optimal before luciferase activity was measured in cell lysates. Under these conditions, infection by vΔC6 induced significantly greater luciferase activity than did wt VACV. Immunoblotting for VACV protein D8 showed that the virus infections were equivalent and immunoblotting for GAPDH showed equal loading of samples. This experiment was conducted using either crude or purified virus preparations (n = 4) and in each case a significant difference between the viruses was observed (Fig 9A).

The second method exploited the ability of the IRF9-S2C protein to activate ISRE promoter within the nucleus and downstream of the position at which the VH1 phosphatase mediates
inhibition of the JAK-STAT pathway. Optimisation experiments to determine the amount of
the IRF9-S2C plasmid to transfect and the length of time after transfection prior to virus infec-
tion showed that this potent inducer of ISRE-dependent gene expression was best only trans-
fecting a few hours before infection because overnight transfection induced very high levels of
luciferase activity. Transfection of the IRF9-S2C plasmid for 4 h induced a modest 2-fold
induction in luciferase activity and this was increased further by virus infection (Fig 9B). How-
ever, following virus infection for 5 h, wt VACV induced lower levels of luciferase than vΔC6,
as in Fig 9A. These significant differences were seen reproducibly in multiple experiments
(n = 4). Immunoblotting confirmed equal infection and protein loading.

Collectively, these data show that during VACV infection protein C6 is able to diminish
expression from the ISRE promoter over and above the effect of the VH1 phosphatase.

Fig 9. Protein C6 inhibits ISRE-dependent gene expression during VACV infection. (A) Multiple wells
(n = 6 per condition) of a 96-well plate containing HEK293T cells were transfected with plasmids expressing
firefly luciferase under the control of an ISRE promoter and a plasmid constitutively expressing renilla
luciferase. Sixteen h post transfection, cells were either mock-infected or infected with vΔC6 or wt VACV at 5
PFU/cell and 5 h later the cells were harvested and the expression of firefly luciferase was measured and
normalised to renilla luciferase expression. ****P<0.0001. (B) Lysates from cells treated as in (A) were
subjected to SDS-PAGE and immunoblotting for VACV proteins D8 and C6, and for cellular GAPDH. (C)
HEK293T cells were transfected by the same plasmids as described in (A) and 16 h later the cells were
transfected with 100 ng/well (96-well plate) of a plasmid expressing IRF9-S2C for 4 h. The cells were then
infected with vΔC6 or wt VACV at 5 PFU/cell for 5 h. The expression of firefly luciferase was measured and
normalised to renilla luciferase expression. **P<0.01. (D) Lysates from cells treated as in (C) were analysed
by SDS-PAGE and immunoblotting as in (B). In (B) and (D) the positions of molecular mass markers are
shown in kDa on the left.

doi:10.1371/journal.ppat.1005955.g009
Discussion

Previously, C6 was identified as a VACV immunomodulator and virulence factor and was shown to inhibit the induction of type I IFNs through inhibition of the IRF-3/7 signalling pathway at the level of the TBK1/IKKe kinase complex [26]. This study identifies a second function for VACV protein C6 as an inhibitor of the cellular response to type I IFN. Data presented demonstrate that C6 inhibits IFNα-induced expression of ISGs at both the mRNA and protein level (Fig 1). The inability of a pharmacological inhibitor of TBK1/IKKe to reduce IFNα-induced reporter gene expression (S2 Fig) indicates that inhibition of this kinase complex by C6 is unlikely to explain the ability of C6 to also inhibit the cellular response to IFNα. Therefore, to elucidate the mechanism by which C6 has its inhibitory effect on this second pathway, the IFNα-induced phosphorylation and nuclear translocation of STAT1 and STAT2 were examined and C6 was found to have no effect on these early events of this signalling pathway (Figs 2, 4 and 5). Furthermore, both endogenous STAT2 and a constitutively active ISGF3 mimic, IRF-9-S2C, were still able to bind to the ISRE in the presence of C6 (Fig 7), indicating C6 exerts its inhibitory effect after ISGF3 binding to the ISRE. Interestingly, C6 interacts with STAT2 (Fig 8A–8C) and the transactivation domain (aa 747–851) of STAT2 fused to IRF-9 (Fig 8D) but not with STAT1 or IRF-9 (Fig 8A). The STAT2 transactivation domain is known to be required for the recruitment of chromatin modifiers and transcriptional machinery [37]. Therefore, the ability of C6 to interact specifically with this domain gives insight into how this viral protein may inhibit this crucial signalling pathway at such a late stage.

C6 is one of many VACV proteins that inhibit the IFN response, however, it is the first such protein known to inhibit both branches of the IFN response, inhibiting both IFNβ production and the cellular responses to type I IFN. C6 is also the first VACV protein identified to inhibit the response to type I IFN in the nucleus of infected cells; VACV inhibitors to date act early in the JAK/STAT signalling pathway, either extracellularly to prevent binding of secreted type I IFN to their receptor (B18) [13–15], or in the cytoplasm of infected cells to dephosphorylate activated STAT1 and STAT2 (VH1) [17,18]. C6 instead acts at a very late stage in the pathway, after the ISGF3 complex has formed, translocated into the nucleus and bound to the ISRE. Despite this, its inhibitory action was evident on 6 out of 7 of the ISGs examined, suggesting that the protein or step it targets is required for the induction of many ISGs.

The requirement for many protein inhibitors of a single, albeit important, signalling pathway is not well understood. However, VACV shows a similar ‘belt and braces’ approach to other signalling pathways, for example the NF-κB pathway, for which it is currently known to possess 10 inhibitors [9–12,23,29,30,38–42]. These proteins are not completely redundant however, as they cause virus attenuation in vivo when deleted individually [10,11,39,43–47]. Similarly, previous work has shown that deletion of C6 leads to an attenuated phenotype in both intradermal and intranasal models of VACV infection in mice [26], despite the presence of other IFN-signalling inhibitors. The identification of a second function of C6 means that the observed attenuation of the C6 deletion virus cannot be attributed to a single function as yet, but highlights the importance of this immunomodulatory protein. Structure-based mutagenesis of C6 may enable the dissection of these different activities as was done for the related VACV protein N1 [30].

The use of multiple proteins to inhibit a single pathway may be explained in many ways, such as the possibility of incomplete inhibition by any one protein, or the requirement for different immunomodulators in different cell types or infection stages. It could also be explained by possible crosstalk between innate immune signalling pathways meaning that inhibition of a pathway at a certain point could be overcome by activation of another communicating immune signalling pathway. However, the late stage at which C6 inhibits the type I IFN response would
suggest that cross talk from other pathways would still be unable to activate ISGF3-driven ISG transcription in the presence of C6. The role of C6 in inhibiting the JAK-STAT3-driven ISG transcription may be masked to some degree by the effect of VH1 that dephosphorylates STAT1 and STAT2 rapidly after infection. VH1 is an essential gene for VACV replication [16], preventing its elimination by genetic manipulation. Nonetheless analysis of ISRE-driven gene expression early after infection with either wild type virus or a mutant virus lacking C6 showed a functional role for the C6 protein in diminishing ISRE-dependent gene expression (Fig 9). The roles of VH1 and C6 are therefore complementary. VH1 is expressed late in infection and packaged into the virion, whereas C6 is an early VACV protein, expressed from approximately 2 h post infection. These differential expression patterns might explain the requirement of both inhibitors, perhaps with their relative importance differing over the life cycle of the virus.

The principal transcriptional activating complex responsible for type I IFN-induced gene expression, ISGF3, consists of three components, STAT1, STAT2 and IRF-9. In this complex, STAT2 provides a potent and essential transcriptional activation domain [48]. The mechanistic process by which ISGF3, likely through this C-terminal domain of STAT2, signals to and promotes transcription of ISGs by RNA polymerase II remains unclear. However, a number of cellular proteins known to have roles in transcription, such as components of the Mediator complex [49], or chromatin modification, including histone deacetylases (HDACs) [50], histone acetyltransferases (HATs) [51] and chromatin remodeling complexes [52–55], have been identified as being essential for ISGF3-driven transcription. The precise mechanism by which C6 inhibits JAK/STAT signalling remains to be determined, however it is possible that the association of C6 with the STAT2-transactivation domain could prevent or alter the interactions of STAT2 with these or other cellular proteins required for ISG transcriptional induction. Indeed some such proteins have been shown to bind directly to the STAT2 transactivation domain, for example the HATs p300/CREB [51] and GCN5 [56]. In the future, further work is needed to assess the exact consequence of the C6-STAT2 TAD interaction.

The importance of the IFN-signalling pathway in preventing viral replication and spread dictates that the majority of mammalian viruses have one or multiple mechanisms of inhibiting the response of infected cells to type I IFN. There is an array of different mechanisms by which viral proteins inhibit JAK/STAT signalling, some of which are reviewed in [4]. Many such mechanisms focus on inhibiting the early steps in the JAK/STAT signalling pathway, by degradation of either STAT1 or STAT2 as with PiV5 [32] and PiV2 V proteins [57], respiratory syncytial virus NS1 and NS2 proteins [58] and dengue NS5 protein [59], by inhibition of STAT phosphorylation as with Sendai virus C protein [60], or by cytoplasmic sequestration of the ISGF3 complex as with NiV [31] and Hendra virus [61] V proteins.

Fewer viral proteins have been identified that inhibit the later stages of this signalling pathway, once the ISGF3 complex has reached the nucleus. The human cytomegalovirus (HCMV) IE1 protein interacts with STAT2 and inhibits the binding of STAT2 and promyelocytic leukemia protein (PML), a protein that associates with STAT1, STAT2, and HDACs, to ISG promoters [62]. Therefore, HCMV IE1 delivers its inhibitory action within the nucleus and via an interaction with STAT2, but again upstream of the inhibitory action of C6. Conversely, adeno-virus E1A protein has its inhibitory effect, like C6, downstream of ISGF3- promoter binding but does so through interacting with and preventing the functioning of HATs and histone ubiquitylating complexes required for full ISG transcriptional activation and not through a direct interaction with STAT2 [63]. Similarly, influenza A virus nonstructural protein 1 (NS1) inhibits the cellular response to type I IFNs in the nucleus through interaction with a complex involved in transcriptional elongation, hPAF1C and once again not by a direct interaction with STAT2 [64]. Interestingly, NS1 inhibits type I IFN production through binding dsRNA produced by the virus and thus preventing its detection by PRRs [65–67]. NS1 and C6 have
therefore both evolved to inhibit both type I IFN production and type I IFN-induced signalling but by distinct mechanisms in each pathway.

To our knowledge VACV protein C6 is the first viral protein shown to both associate with the STAT2 transactivation domain and inhibit IFNα-dependent ISG induction after ISGF3 binding to the ISRE. The sequence of events that occur following ISGF3 binding to the ISRE is poorly understood and further elucidating the mechanism by which C6 inhibits this signalling pathway in the nucleus may enhance our knowledge of the late stages of the type I IFN signalling pathway. Lastly, it is notable that although VACV is a cytoplasmic DNA virus, it has evolved mechanisms to inhibit IFN production or activity within both the cytoplasm and the nucleus and indeed outside the infected cell by the expression of soluble type I and type II IFN binding proteins.

Materials and Methods

Cell lines and viruses

HEK293T (ATCC CRL-11268) cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) with 10% heat treated (56°C, 1 h) foetal bovine serum (FBS, Seralab) and penicillin/streptomycin (P/S, 50 μg/ml, PAA laboratories). HeLa (ATCC CCL-2) cells were maintained in Minimum Essential Medium (MEM, Invitrogen) supplemented with 10% FBS, P/S and 1:100 non-essential amino acids (Gibco).

HeLa cells stably expressing GFP only or in combination with V5-tagged C6 (V5-C6), V5-Parainfluenza virus 5 V protein (V5-PiV5-V) or V5-tagged B14 (V5-B14), were obtained after transduction of cells with lentiviruses (see below) and sorting to obtain GFP-positive cells in a MoFlo MLS high-speed cell sorter (Beckman Coulter). For each protein two populations were sorted based on GFP expression level; the top 30% of GFP-expressing cells (high expressers) and the next 30% (middle expressers). Immunoblot analysis was used to determine the expression levels of the protein of interest in these two populations. Based on the observed expression of these proteins, the high GFP-expressing populations were chosen for, EV (GFP only), V5-C6, and V5-PiV5-V and the middle GFP-expressing V5-B14 population. For protein expression level of cell lines see S1C Fig. Lentivirus particles for transduction were generated after transient co-transfection of HEK293T cells with entry and packaging vectors and the bicistronic genomic vector encoding GFP and the appropriate V5 tagged protein using PEI (CellnTec).

The recombinant VACV Western Reserve strain C6-TAP and N1-TAP viruses were described [68]. The tandem-affinity purification (TAP) tag used here and in plasmids described below contains 2 copies of the streptavidin-binding sequence and 1 copy of the FLAG epitope [69]. Wild type (wt) VACV strain WR and the deletion mutant lacking the C6L gene were described [26].

Antibodies and reagents

Antibodies used were from the following sources; Rabbit (Rb) anti-FLAG (Sigma-Aldrich, F7425, diluted 1:5000), Mouse (Ms) anti-V5 (AbD Serotec Ltd, MCA1360, diluted 1:5000), Rb anti-HA (Sigma Aldrich, H6908, diluted 1:1000), Ms anti-α-tubulin (Millipore, 05–829, diluted 1:5000), Rb anti-actin (Sigma, A2066, diluted 1:1000), Ms anti-Phospho-STAT1 (Invitrogen, 333400, diluted 1:750), Rb anti-phospho-STAT2 (Millipore, 07–224, diluted 1:1000), Rb anti-STAT1 for immunofluorescence (Millipore, 06–501, diluted 1:300), Rb anti-STAT1 for western blotting (Cell signalling, 9172S, diluted 1:1000), Rb anti-STAT1 for immunoprecipitation (Santa Cruz, sc-345, diluted 1:100), Rb anti-STAT2 (Santa Cruz, sc-476, diluted 1:100 for immunofluorescence and 1:500 for western blotting), Ms anti-Ku70 (Abcam,
ab3114, diluted 1:1000), Ms anti-IFIT1 for flow cytometry (Abcam, ab70023, 1:500), and Alexa Fluor 546 goat anti-Rb IgG (H+L) (Invitrogen, A-11010, diluted 1:750 for immunoblotting) or Alexa Fluor 647 donkey anti-Ms IgG (H+L) (Invitrogen, A-31571, diluted 1:2000 for flow cytometry).

Reagents used in this study were BX795 (Tocris), poly(I:C) (InvivoGen), Protein G Sepharose 4 Fast Flow (GE Healthcare), High Capacity Streptavidin Agarose Resin (Thermo Scientific), human IFNα and human IL-1β were from Peprotech, poly(dI:dC) and ANTI-FLAG M2 Affinity Gel were from Sigma Aldrich. Biotinylated DNA for immunoprecipitations were synthesised by Integrated DNA technologies. The sequences were ISREcore; TGCCTCGGGAACCGAAACTGAAGCCA and ISRErandom ACTGATCGGAAACC GAAACGATCTATG. These sequences were taken from [36].

Plasmids
Codon-optimised TAP-C6 and N1-TAP, were described previously [68] and [30]. B14-TAP was kindly provided by Dr. Brian Ferguson (Department of Pathology, University of Cambridge, UK). The sequence of PiV5-V and NiV-V were amplified by PCR from plasmids kindly provided by Prof. Richard Randall (University of St Andrews, UK) and then subcloned into mammalian expression vectors pcDNA3.1 (Invitrogen) with an N-terminal V5 tag. V5-C6 was produced by PCR amplification of C6 from VACV WR DNA and cloned into pcDNA3.1. GFP-V5 was provided by Dr. Christian Ku (Department of Pathology, University of Cambridge). The sequences of IRF-9, STAT1 and STAT2 were amplified by PCR from HeLa cDNA and subcloned into mammalian expression vector pcDNA4/TO with a C-terminal TAP tag and/or vector pcDNA3.1 with a N-terminal HA tag. pcDNA3 IRF9-STAT2C was a gift from Prof. Curt Horvath (Addgene plasmid 37544) [35]. pcDNA4/TO (Invitrogen) was used in luciferase reporter assays as EV. ISRE-luciferase, NF-κB-Luciferase, and TK renilla were obtained from Dr. Andrew Bowie (Trinity College, Dublin, Ireland), and ISG56.1-Luciferase was from Ganeth Sen (Lerner Research Institute, Ohio, USA).

Reporter gene assays
Reporter gene assays were performed in HeLa or HEK293T cells seeded in 96-well plates. Cells were transfected with 100 ng firefly luciferase reporter plasmid, 10 ng GL3-renilla luciferase plasmid and 100 ng of expression plasmid for the protein of interest. For the BX795 reporter gene assay only the firefly report plasmid and GL3-Renilla plasmids were transfected. For the IRF9-S2C reporter gene assays 100 ng firefly reporter plasmid and 10 ng GL3-Renilla plasmid were transfected along with 50 ng IRF9-S2C and 50 ng C6 expression vector or control plasmids, except in the empty vector only control where 100 ng pcDNA4 was transfected only. Transit-LT1 (Mirus, 2 µl per 1 µg DNA) was used for transfection of HeLa cells and PEI (CellInTec, 2 µl per 1 µg DNA) for HEK-293T cells. Sixteen hours post transfection cells were stimulated as indicated in the figure legends. Cells were harvested in passive lysis buffer (Promega, 100 µl/well). The firefly-luciferase readings of each sample were normalised to the renilla-luciferase readings and fold inductions were calculated relative to the non-stimulated controls for each plasmid. Experiments were performed in triplicate and conducted at least 3 times.

Real time PCR
HeLa cell lines stably expressing the proteins of interest were grown in 12-well plates and RNA was extracted using the RNeasy kit (QIAGEN). One µg of each RNA sample was used to synthesise cDNA using Superscript III reverse transcriptase according to the manufacturer’s
protocol (Invitrogen). ISG mRNA was quantified by real-time PCR using a ViiA 7 Real-Time PCR System (Life Technologies), fast SYBR Green Master Mix (Applied Biosystems) and the following primers, IFIT1 (Fwd: CCTGAAAGCCAGAATGAGG, Rev: TCCACCTTGTC CAGGTAAAGT) IFIT3 (Fwd: ACACAGAGGGCAGTCATGAGTG, Rev: TGAATAGTTC CAGGTGAAATGGC) MxA (Fwd: ATCCCTGGGATTT TGGGGCTT, Rev: CGGCTTGTGC GCTGGTGTCG) GAPDH Fwd: ACCCAGAAGACTGTGGATGG, Rev: TTCTAGACGG CAGGTCAGGT). Amplification of ISGs was normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) amplification from the same sample, and the fold induction of genes in response to IFNα was calculated relative to the unstimulated control of the cell line. Experiments were performed in biological triplicate and conducted three times.

Flow cytometry

HeLa cells stably expressing the proteins of interest were grown in 6-cm dishes and stimulated with 500 U/ml IFNα or mock-stimulated for 8 h. Cells were removed from the dishes by addition of trypsin (GIBCO), transferred to Eppendorf tubes and washed twice with ice-cold PBS. Cells were fixed in 4% paraformaldehyde and permeabilised with 0.1% Triton X. Cells were then incubated with anti-IFIT1 (Abcam, ab70023) in Triton buffer (0.5% BSA, 0.02% sodium azide, 0.1% Triton X-100 in PBS) for 1 h at 4°C. Cells were washed twice with Triton buffer and then incubated with Alexa 647 Donkey anti-Mouse (Invivogen) in Triton buffer for 1 h in the dark at room temperature. Cells were washed twice in Triton buffer, once in 0.5% BSA in PBS and then analysed on a CyAn ADP Analyser (Beckman coulter). Collected data were analysed using Summit (Beckman Coulter).

Confocal microscopy

HeLa cells stably expressing the proteins of interest were grown on glass coverslips in 6-well plates. Cells were stimulated with 1000 U/ml IFNα for 1 h. Cells were fixed with 4% paraformaldehyde and permeabilised in 0.1% Triton X. Cells were then incubated with blocking buffer (0.5% BSA in PBS) for 30 min, stained with primary antibody for 1 h (STAT1: 1:300, STAT2 1:100 in blocking buffer) and for 1 h with secondary antibody (Alexa 546, Invitrogen). Coverslips were mounted onto microscope slides in Mowiol 4–88 containing 4',6-diamidino-2-phenylindole (DAPI). Slides were visualised and imaged using a Zeiss LSM 780 Confocal microscope. Images were viewed using LSM Image Browser (Zeiss).

Co-immunoprecipitation

HEK293T cells were grown in 10-cm dishes and transfected with the constructs outlined in the figure legends using either Transit LT1 (Mirus) or calcium phosphate transfection. Sixteen hours later cells were stimulated with IFNα or mock-treated as described in figure legends, then lysed in lysis buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.4, 10 mM CaCl2, 0.1% (v/v) Triton-X, 10% (v/v) glycerol and protease (cOmplete Mini, Roche) and phosphatase inhibitors (PhosSTOP, Roche)) and cleared by centrifugation. Samples were then incubated with 30 μl Protein G Sepharose 4 Fast Flow (GE Healthcare) and anti-STAT1 (Santa Cruz, sc-345) for 6 h, or ANTI-FLAG M2 Affinity Gel (Sigma Aldrich) or Anti-HA Agarose (Sigma Aldrich) and 2 h. Immunoprecipitations were washed 3 times in lysis buffer and bound proteins were eluted by boiling in buffer containing SDS. Samples were then analysed by SDS-PAGE (polyacrylamide gel electrophoresis) and immunoblotting with the stated antibodies.
Biotinylated-DNA immunoprecipitation

HEK293T cells were grown in 10-cm dishes and co-transfected with expression plasmids for IRF9-S2C, and V5-NiV-V, V5-C6 or V5-GFP using calcium phosphate transfection in triplicate for each condition. Sixteen hours later cells were lysed in lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 5% glycerol and protease (cOmplete Mini, Roche) and phosphatase (PhosSTOP, Roche) inhibitors). Lysates were incubated firstly with 10 ng/ml poly(dI:dC) for 30 min, then with 100 pmol biotin-labelled ISREcore or biotin-labelled control DNA for 1.5 h and finally with 30 μl High Capacity Streptavidin Agarose Resin (Thermo Scientific) for 3.5 h. Immunoprecipitations were washed four times with lysis buffer and proteins were eluted by boiling in buffer containing SDS. Samples were then analysed by SDS-PAGE and immunoblotting with the stated antibodies.

Statistical analysis

Un-paired student’s T-tests were used to analyse data, with Welch’s correction applied when variances differed significantly between samples. Statistical significance is expressed as:

\[ P < 0.05, \quad **P < 0.01, \quad ***P < 0.001 \text{ and } ****P < 0.0001 \]

Supporting Information

S1 Fig. Expression levels of C6 and control proteins in reporter gene assays and stable cell lines. Immunoblot analysis of protein expression from transiently transfected HEK293T (A) and HeLa (B) cells in a 96-well plate format for dual luciferase assays shown in Fig 1A and 1B, respectively. (C) Expression level of V5-tagged proteins from stably transduced HeLa cell lines used in Figs 1C, 1D, 2 and 4. Immunoblots were performed at least twice and a representative figure is shown. Positions of molecular mass markers are shown to the left of the immunoblots. (TIF)

S2 Fig. Inhibition of TBK1/IKKe does not inhibit IFNα- induced reporter gene expression. HeLa cells were transfected with plasmids expressing firefly luciferase under the control of the stated promoters and constitutively expressing renilla luciferase. Sixteen hours post transfection cells were treated with BX795 (0.5 μM) or DMSO for 3 h, after which they were treated with p: C (20 ug/ml), IL-1β (50 ng/ml), or IFNα (250 U/ml) as appropriate. Results are shown as percentage induction of reporter gene relative to the firefly luciferase induction following appropriate stimulation in DMSO-treated control cells. P<0.001. (TIF)

Author Contributions

Conceptualization: JHS RPS GLS.

Formal analysis: JHS RPS YL JSS.

Funding acquisition: JHS JSS GLS.

Investigation: JHS RPS YL JSS.

Methodology: JHS RPS YL JSS GLS.

Project administration: GLS.

Resources: JHS RPS YL JSS GLS.
Supervision: JHS RPS YL GLS.
Validation: JHS RPS YL JSS.
Visualization: JHS RPS YL JSS GLS.
Writing – original draft: JHS RPS YL GLS.
Writing – review & editing: JHS RPS YL JSS GLS.

References
1. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918–1921. PMID: 8009221
2. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, et al. (1998) Virus infection induces the assembly of coordinately activated transcription factors on the IFN-β enhancer in vivo. Molecular cell 1: 507–518. PMID: 9660935
3. Ivashkov LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14: 36–49. doi: 10.1038/nri3581 PMID: 24362405
4. Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1–47. doi: 10.1099/vir.0.83391-0 PMID: 18089727
5. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication.
6. Moss B (2007) Poxviridae: the viruses and their replication. In: Knipe D. M. H PM, Griffin D. E., Lamb R. A., Martin M. A., Roizman B. & Straus S. E., editor. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2905–2946.
7. Gubser C, Hue S, Kellam P, Smith GL (2004) Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85: 105–117. doi: 10.1099/vir.0.19565-0 PMID: 14718625
8. Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, et al. (2013) Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Virol 94: 2367–2392. doi: 10.1099/vir.0.055921-0 PMID: 23999164
9. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4: e22. doi: 10.1371/journal.ppat.0040022 PMID: 18266467
10. Mansur DS, Maluquer de Motes C, Unterholzer L, Sumner RP, Ferguson BJ, et al. (2013) Poxvirus Targeting of E3 Ligase β-TrCP by Molecular Mimicry: A Mechanism to Inhibit NF-κB Activation and Promote Immune Evasion and Virulence. PLoS Pathog 9.
11. Stack J, Haga IR, Schröder M, Bartlett NW, Maloney G, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like–interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007–1018. doi: 10.1084/jem.20041442 PMID: 15767367
12. Schroder M, Baran M, Bowie AG (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKK epsilon-mediated IRF activation. Embo J 27: 2147–2157. doi: 10.1038/emboj.2008.145 PMID: 18636090
13. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270: 15974–15978. PMID: 7608155
14. Symons JA, Alcamo A, Smith GL (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81: 551–560. PMID: 7758109
15. Alcamo A, Symons JA, Smith GL (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74: 11230–11239. PMID: 11070021
16. Liu K, Lemon B, Traktman P (1995) The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. J Virol 69: 7823–7834. PMID: 7494294
17. Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75: 3185–3196. doi: 10.1128/JVI.75.7.3185-3196.2001 PMID: 11236845
18. Mann BA, Huang JH, Li P, Chang H-C, Slee RB, et al. (2008) Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. Journal of Interferon & Cytokine Research 28: 367–380.
19. Gonzalez JM, Esteban M (2010) A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 7: 59. doi: 10.1186/1743-422X-7-59 PMID: 20230632

20. Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, et al. (2008) Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4: e1000128. doi: 10.1371/journal.ppat.1000128 PMID: 18704168

21. Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, et al. (2007) Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 16: 118–124. doi: 10.1110/ps.062454707 PMID: 17123957

22. Kvansakul M, Yang H, Fairlie WD, Czabarka PE, Fischer SF, et al. (2008) Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 15: 1564–1571. doi: 10.1038/cdd.2008.83 PMID: 18551131

23. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, et al. (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88: 1656–1666. doi: 10.1099/vir.0.82772-0 PMID: 17485524

24. Neidel S, Maluquer de Motes C, Mansur DS, Strnadova P, Smith GL, et al. (2015) Vaccinia virus protein A49 is an unexpected member of the B-cell Lymphoma (Bcl)-2 family. J Biol Chem 290: 5991–6002. doi: 10.1074/jbc.M114.624650 PMID: 25605733

25. Smith GL, Chan YS, Howard ST (1991) Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J Gen Virol 72 (Pt 6): 1349–1376.

26. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, et al. (2011) Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7: e1002247. doi: 10.1371/journal.ppat.1002247 PMID: 21931555

27. Sumner RP, Ren H, Smith GL (2013) Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol 94: 1121–1126. doi: 10.1099/vir.0.049700-0 PMID: 23288427

28. Garcia-Arziaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, et al. (2011) A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6: e24244. doi: 10.1371/journal.pone.0024244 PMID: 21909386

29. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, et al. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279: 36570–36578. doi: 10.1074/jbc.M400567200 PMID: 15215253

30. Maluquer de Motes C, Cooray S, Ren H, Almeida GM, McGourt K, et al. (2011) Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7: e1002430. doi: 10.1371/journal.ppat.1002430 PMID: 22194685

31. Rodriguez JJ, Parisien JP, Horvath CM (2002) Nipah Virus V Protein Evades Alpha and Gamma Interferons by Preventing STAT1 and STAT2 Activation and Nuclear Accumulation. J Virol 76: 11476–11483. doi: 10.1128/JVI.76.22.11476-11483.2002 PMID: 12388709

32. Didcock L, Young DF, Goodburn S, Randall RE (1999) The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol 73: 9928–9933. PMID: 10559305

33. Grandvaux N, Servant MJ, ten Oever BR, Sen GC, Balachandran S, et al. (2002) Transcriptional Profiling of Interferon Regulatory Factor 3 Target Genes: Direct Involvement in the Regulation of Interferon-Stimulated Genes. J Virol 76: 5532–5539. doi: 10.1128/JVI.76.11.5532-5539.2002 PMID: 11991981

34. tenOever BR, Ng S-L, Chua MA, McWhirtier SM, García-Sastre A, et al. (2007) Multiple Functions of the IKK-Related Kinase IKKe in Interferon-Mediated Antiviral Immunity. Science 315: 1274–1278. doi: 10.1126/science.1136567 PMID: 17332413

35. Kraus TA, Lau JF, Parisien JP, Horvath CM (2003) A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J Biol Chem 278: 13033–13038. doi: 10.1074/jbc.M212972200 PMID: 12574168

36. Schmid S, Mordstein M, Kochs G, García-Sastre A, ten Oever BR (2010) Transcription Factor Redundancy Ensures Induction of the Antiviral State. Science 315: 1274–1278. doi: 10.1126/science.1136567 PMID: 17332413

37. Bluyssen HA, Levy DE (1997) Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J Biol Chem 272: 4600–4605. PMID: 9020188
38. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J (2009) Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J Virol 83: 6757–6768. doi: 10.1128/JVI.02570-08 PMID: 19369349
39. Ember SW, Ren H, Ferguson BJ, Smith GL (2012) Vaccinia virus protein C4 inhibits NF-kappaB activation and promotes virus virulence. J Gen Virol 93: 2098–2108. doi: 10.1099/vir.0.045070-0 PMID: 22791606
40. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, et al. (2000) A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 97: 10162–10167. doi: 10.1073/pnas.160027697 PMID: 10920188
41. Shisler JL, Jin XL (2004) The Vaccinia Virus K1L Gene Product Inhibits Host NF-κB Activation by Preventing IκBα Degradation. J Virol 78: 3553–3560. doi: 10.1128/JVI.78.7.3553-3560.2004 PMID: 15016878
42. Gedey R, Jin XL, Hinthong O, Shisler JL (2006) Poxviral Regulation of the Host NF-κB Response: the Vaccinia Virus M2L Protein Inhibits Induction of NF-κB Activation via an ERK2 Pathway in Virus-Infected Human Embryonic Kidney Cells. J Virol 80: 8676–8685. doi: 10.1128/JVI.00935-06 PMID: 16912315
43. Chen RA, Jacobs N, Smith GL (2006) Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87: 1451–1458. doi: 10.1099/vir.0.81736-0 PMID: 16690909
44. Benfield CT, Ren H, Lucas SJ, Bahsoun B, Smith GL (2013) Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol 94: 1647–1657. doi: 10.1128/JVI.00935-06 PMID: 23580427
45. Brandt TA, Jacobs BL (2001) Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75: 850–856. doi: 10.1128/JVI.75.2.850-856.2001 PMID: 11134298
46. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, et al. (2003) The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197: 343–351. doi: 10.1084/jem.20021652 PMID: 12566418
47. Bartlett N, Symons JA, Charske DC, Smith GL (2002) The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83: 1965–1976. doi: 10.1099/0022-1317-83-8-1965 PMID: 12124460
48. Qureshi SA, Leung S, Kerr IM, Stark GR, Darnell JE Jr. (1996) Function of Stat2 protein in transcriptional activation by alpha interferon. Mol Cell Biol 16: 288–293. PMID: 8524306
49. Lau JF, Nusinzon I, Burakov D, Freedman LP, Horvath CM (2003) Role of Metazoan Mediator Proteins in Interferon-Responsive Transcription. Mol Cell Biol 23: 620–628. doi: 10.1128/MCB.23.2.620-628.2003 PMID: 12509459
50. Nusinzon I, Horvath CM (2003) Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci U S A 100: 14742–14747. doi: 10.1073/pnas.2433987100 PMID: 14645718
51. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, et al. (1996) Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α. Nature 383: 344–347. doi: 10.1038/383344a0 PMID: 8848048
52. Huang M, Qian F, Hu Y, Ang C, Li Z, et al. (2002) Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol 4: 774–781. doi: 10.1038/ncb855 PMID: 12244326
53. Cui K, Tailor P, Liu H, Chen X, Ozato K, et al. (2004) The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. Mol Cell Biol 24: 4476–4486. doi: 10.1128/MCB.24.10.4476-4486.2004 PMID: 15121865
54. Gnatovskiy L, Mita P, Levy DE (2013) The human RVB complex is required for efficient transcription of type I interferon-stimulated genes. Mol Cell Biol 33: 3817–3825. doi: 10.1128/MCB.01562-12 PMID: 23878400
55. Liu H, Kang H, Liu R, Chen X, Zhao K (2002) Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol Cell Biol 22: 6471–6479. doi: 10.1128/MCB.22.18.6471-6479.2002 PMID: 12192045
56. Paulson M, Press C, Smith E, Tanese N, Levy DE (2002) IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol 4: 140–147. doi: 10.1038/ncb747 PMID: 11802163
57. Parisien JP, Lau JF, Rodriguez JJ, Sullivan BM, Moscona A, et al. (2001) The V protein of human para-influenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 283: 230–239. doi: 10.1006/viro.2001.0856 PMID: 11336548
58. Lo MS, Brazas RM, Holtzman MJ (2005) Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Mediate Inhibition of Stat2 Expression and Alpha/Beta Interferon Responsiveness. J Virol 79: 9315–9319. doi: 10.1128/JVI.79.14.9315-9319.2005 PMID: 15994826

59. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A (2009) NSS of dengue virus mediates STAT2 binding and degradation. J Virol 83: 5408–5418. doi: 10.1128/JVI.02188-08 PMID: 19279106

60. Komatsu T, Takeuchi K, Yokoo J, Gotoh B (2002) Sendai virus C protein impairs both phosphorylation and dephosphorylation processes of Stat1. FEBS Lett 511: 139–144. PMID: 11821064

61. Rodriguez JJ, Wang LF, Horvath CM (2003) Hendra Virus V Protein Inhibits Interferon Signaling by Preventing STAT1 and STAT2 Nuclear Accumulation. J Virol 77: 11842–11845. doi: 10.1128/JVI.77.21.11842-11845.2003 PMID: 14557668

62. Kim YE, Ahn JH (2015) Positive role of promyelocytic leukemia protein in type I interferon response and its regulation by human cytomegalovirus. PLoS Pathog 11: e1004785. doi: 10.1371/journal.ppat.1004785 PMID: 25812002

63. Fonseca GJ, Thillainadesan G, Yousef AF, Ablack JN, Mossman KL, et al. (2012) Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification. Cell Host Microbe 11: 597–606. doi: 10.1016/j.chom.2012.05.005 PMID: 22704620

64. Marazzi I, Ho JSY, Kim J, Manicassamy B, Dewell S, et al. (2012) Suppression of the antiviral response by an influenza histone mimic. Nature 483: 428–433. doi: 10.1038/nature10892 PMID: 22419161

65. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr., et al. (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81: 514–524. doi: 10.1128/JVI.01265-06 PMID: 17079289

66. Opitz B, Rejaibi A, Dauber B, Eckhard J, Vinzing M, et al. (2007) IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell Microbiol 9: 930–938. doi: 10.1111/j.1462-5822.2006.00841.x PMID: 17140406

67. Guo Z, Chen L-m, Zeng H, Gomez JA, Plowden J, et al. (2007) NS1 Protein of Influenza A Virus Inhibits the Function of Intracytoplasmic Pathogen Sensor, RIG-I. American Journal of Respiratory Cell and Molecular Biology 36: 263–269. doi: 10.1165/rccmb.2006-0283RC PMID: 17053203

68. Maluquer de Motes C, Schiffrer T, Sumner RP, Smith GL (2014) Vaccinia virus virulence factor N1 can be ubiquitylated on multiple lysine residues. J Gen Virol 95: 2038–2049. doi: 10.1099/vir.0.065664-0 PMID: 24914067

69. Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7: 4228–4234. doi: 10.1002/pmic.200700038 PMID: 17979178